Market Overview

ArQule To Be Acquired By Merck For $2.7B

ArQule To Be Acquired By Merck For $2.7B

Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion.

ArQule is a biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases.

See Also: 12 Biotech Stocks Primed For A Short Squeeze

“ArQule’s focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties,” said Dr. Roger Perlmutter, president, Merck Research Laboratories in a statement. “This acquisition strengthens Merck’s pipeline with the addition of these strategic assets including, most notably, ARQ 531, a compelling candidate for the treatment of B-cell malignancies.”

Merck shares were trading 0.14% higher at $88.97 in Monday's pre-market session. The stock has a 52-week high of $89.24 and a 52-week low of $70.89.

ArQule's stock traded higher by 101% to $19.50 at time of publication.

Posted-In: Biotech M&A News General Best of Benzinga


Related Articles (ARQL + MRK)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at